This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

This study has been completed.
Information provided by:
Basilea Pharmaceutica Identifier:
First received: July 26, 2005
Last updated: July 16, 2010
Last verified: July 2010
The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis.

Condition Intervention Phase
Hand Dermatoses Drug: alitretinoin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis

Resource links provided by NLM:

Further study details as provided by Basilea Pharmaceutica:

Primary Outcome Measures:
  • Physicians global assessment
  • at week 12 or 24

Secondary Outcome Measures:
  • Response rate per treatment group
  • Modified total lesion symptom score
  • Patients global assessment
  • at week 12 or 24
  • Time to relapse

Estimated Enrollment: 1035
Study Start Date: December 2004
Study Completion Date: September 2007
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Chronic hand dermatitis (CHaD) is a frequent and distressing disease. Conventional treatments yield mostly unsatisfactory results. In addition, chronic hand dermatitis leads to 2-5% of all applications for permanent disability pensions in some western countries. In a therapeutic dose finding study alitretinoin was clinically effective for patients with moderate to severe chronic hand dermatitis refractory to topical treatment.

Patients with severe refractory CHaD will be allocated either of two active treatments or placebo. The primary objective is to demonstrate the response rate based on physicians global assessment of the disease.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic hand dermatitis, all types including hyperkeratotic, vesicular, fingertip dermatitis
  • Lasting for 6 months since initial diagnosis
  • Rated severe
  • Refractory to standard therapy including non-medicated therapy and avoidance of irritants and allergens
  • Refractory to topical steroids

Exclusion Criteria:

  • Female patients who are pregnant or want to become pregnant
  • Female patients of child bearing potential who cannot use or will not commit to using two effective forms of contraception simultaneously
  • Patients whose disease is adequately controlled by standard non-medicated therapy and standard corticosteroid therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00124475

Thomas Ruzicka, MD
Düsseldorf, Germany, 40225
Sponsors and Collaborators
Basilea Pharmaceutica
Principal Investigator: Thomas Ruzicka, MD University of Düsseldorf, Dermatological Hospital, Germany
  More Information

Publications: Identifier: NCT00124475     History of Changes
Other Study ID Numbers: BAP00089
Study First Received: July 26, 2005
Last Updated: July 16, 2010

Keywords provided by Basilea Pharmaceutica:
Chronic Hand Dermatitis

Additional relevant MeSH terms:
Skin Diseases
Hand Dermatoses
Antineoplastic Agents processed this record on September 21, 2017